{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:25:42Z","timestamp":1789147542891,"version":"build-2803163510"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Biomed Sci"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Hesperetin was reported to selectively inhibit phosphodiesterase 4 (PDE4). While hesperetin-7,3'-<jats:italic>O<\/jats:italic>-dimethylether (HDME) is a synthetic liposoluble hesperetin. Therefore, we were interested in investigating its selectivity on PDE4 and binding ability on high-affinity rolipram-binding sites (HARBs)<jats:italic>in vitro<\/jats:italic>, and its effects on ovalbumin-induced airway hyperresponsiveness<jats:italic>in vivo<\/jats:italic>, and clarifying its potential for treating asthma and chronic obstructive pulmonary disease (COPD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PDE1~5 activities were measured using a two-step procedure. The binding of HDME on high-affinity rolipram-binding sites was determined by replacing 2 nM [<jats:sup>3<\/jats:sup><jats:italic>H<\/jats:italic>]-rolipram. AHR was assessed using the FlexiVent system and barometric plethysmography. Inflammatory cells were counted using a hemocytometer. Cytokines were determined using mouse T helper (Th)1\/Th2 cytokine CBA kits, and total immunoglobulin (Ig)E or IgG<jats:sub>2a<\/jats:sub>levels were done using ELISA method. Xylazine (10 mg\/kg)\/ketamine (70 mg\/kg)-induced anesthesia was performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>HDME revealed selective phosphodiesterase 4 (PDE4) inhibition with a therapeutic (PDE4<jats:sub>H<\/jats:sub>\/PDE4<jats:sub>L<\/jats:sub>) ratio of 35.5<jats:italic>in vitro<\/jats:italic>.<jats:italic>In vivo<\/jats:italic>, HDME (3~30 \u03bcmol\/kg, orally (p.o.)) dose-dependently and significantly attenuated the airway resistance (R<jats:sub>L<\/jats:sub>) and increased lung dynamic compliance (C<jats:sub>dyn<\/jats:sub>), and decreased enhanced pause (P<jats:sub>enh<\/jats:sub>) values induced by methacholine in sensitized and challenged mice. It also significantly suppressed the increases in the numbers of total inflammatory cells, macrophages, lymphocytes, neutrophils, and eosinophils, and levels of cytokines, including interleukin (IL)-2, IL-4, IL-5, interferon-\u03b3, and tumor necrosis factor-\u03b1 in bronchoalveolar lavage fluid (BALF) of these mice. In addition, HDME (3~30 \u03bcmol\/kg, p.o.) dose-dependently and significantly suppressed total and ovalbumin-specific immunoglobulin (Ig)E levels in the BALF and serum, and enhanced IgG<jats:sub>2a<\/jats:sub>level in the serum of these mice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>HDME exerted anti-inflammatory effects, including suppression of AHR, and reduced expressions of inflammatory cells and cytokines in this murine model, which appears to be suitable for studying the effects of drugs on atypical asthma and COPD, and for screening those on typical asthma. However, HDME did not influnce xylazine\/ketamine-induced anesthesia. Thus HDME may have the potential for use in treating typical and atypical asthma, and COPD.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1423-0127-18-84","type":"journal-article","created":{"date-parts":[[2011,11,30]],"date-time":"2011-11-30T04:35:17Z","timestamp":1322627717000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Hesperetin-7,3'-O-dimethylether selectively inhibits phosphodiesterase 4 and effectively suppresses ovalbumin-induced airway hyperresponsiveness with a high therapeutic ratio"],"prefix":"10.1186","volume":"18","author":[{"given":"You-Lan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Te","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Hsien","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wun-Chang","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,11,11]]},"reference":[{"key":"331_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0014-5793(02)03396-3","volume":"530","author":"ME Lee","year":"2002","unstructured":"Lee ME, Markowitz J, Lee JO, Lee H: Crystal structure of phosphodiesterase 4D and inhibitor complex (1). FEBS Lett. 2002, 530: 53-58. 10.1016\/S0014-5793(02)03396-3.","journal-title":"FEBS Lett"},{"key":"331_CR2","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0026-895X(25)09968-7","volume":"37","author":"TJ Torphy","year":"1990","unstructured":"Torphy TJ, Cieslinski LB: Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle. Mol Pharmacol. 1990, 37: 206-214.","journal-title":"Mol Pharmacol"},{"key":"331_CR3","first-page":"685","volume":"49","author":"Z Kapui","year":"1999","unstructured":"Kapui Z, Schaeffer P, Mikus EG, Boronkay E, Gyurky J, Herbert JM, Pascal M: Experimental studies on guanosine 3',5'-cyclic monophosphate levels and airway responsiveness of the novel phosphodiesterase type 5 inhibitor SR 265579 in guinea-pigs. Arzneimittelforschung. 1999, 49: 685-693.","journal-title":"Arzneimittelforschung"},{"key":"331_CR4","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/j.1476-5381.1992.tb14451.x","volume":"106","author":"J de Boer","year":"1992","unstructured":"de Boer J, Philpott AJ, van Amsterdam RG, Shahid M, Zaagsma J, Nicholson CD: Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br J Pharmacol. 1992, 106: 1028-1034.","journal-title":"Br J Pharmacol"},{"key":"331_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0014-2999(88)90753-4","volume":"150","author":"PJ Silver","year":"1988","unstructured":"Silver PJ, Hamel LT, Perrone MH, Bentley RG, Bushover CR, Evans DB: Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur J Pharmacol. 1988, 150: 85-94. 10.1016\/0014-2999(88)90753-4.","journal-title":"Eur J Pharmacol"},{"key":"331_CR6","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/S0960-894X(03)00405-0","volume":"13","author":"E Kim","year":"2003","unstructured":"Kim E, Chun HO, Jung SH, Kim JH, Lee JM, Suh BC, Xiang MX, Rhee CK: Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-asthmatics. Bioorg Med Chem Lett. 2003, 13: 2355-2358. 10.1016\/S0960-894X(03)00405-0.","journal-title":"Bioorg Med Chem Lett"},{"key":"331_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2165\/00003495-200059020-00004","volume":"59","author":"MA Giembycz","year":"2000","unstructured":"Giembycz MA: Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?. Drugs. 2000, 59: 193-212. 10.2165\/00003495-200059020-00004.","journal-title":"Drugs"},{"key":"331_CR8","volume-title":"Pharmacology of Common Chinese Medicine (III)","author":"KY Yen","year":"1971","unstructured":"Yen KY: Pharmacology of Common Chinese Medicine (III). 1971, Taipei: National Research Institute of Chinese Medicine"},{"key":"331_CR9","volume-title":"Inflammation","author":"D Wei","year":"2011","unstructured":"Wei D, Ci X, Chu X, Wei M, Hua S, Deng X: Hesperidin suppresses ovalbumin-induced airway inflammation in a mouse allergic asthma model. Inflammation. 2011,"},{"key":"331_CR10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/ajcn\/76.3.560","volume":"76","author":"P Knekt","year":"2002","unstructured":"Knekt P, Kumpulainen J, Jarvinen R, Rissanen H, Heliovaara M, Reunanen A, Hakulinen T, Aromaa A: Flavonoid intake and risk of chronic diseases. Am J Clin Nutr. 2002, 76: 560-568.","journal-title":"Am J Clin Nutr"},{"key":"331_CR11","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/j.bcp.2004.06.030","volume":"68","author":"WC Ko","year":"2004","unstructured":"Ko WC, Shih CM, Lai YH, Chen JH, Huang HL: Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships. Biochem Pharmacol. 2004, 68: 2087-2094. 10.1016\/j.bcp.2004.06.030.","journal-title":"Biochem Pharmacol"},{"key":"331_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/sj.bjp.0704457","volume":"135","author":"A Robichaud","year":"2002","unstructured":"Robichaud A, Savoie C, Stamatiou PB, Lachance N, Jolicoeur P, Rasori R, Chan CC: Assessing the emetic potential of PDE4 inhibitors in rats. Br J Pharmacol. 2002, 135: 113-118. 10.1038\/sj.bjp.0704457.","journal-title":"Br J Pharmacol"},{"key":"331_CR13","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1172\/JCI0215506","volume":"110","author":"A Robichaud","year":"2002","unstructured":"Robichaud A, Stamatiou PB, Jin SL, Lachance N, MacDonald D, Laliberte F, Liu S, Huang Z, Conti M, Chan CC: Deletion of phosphodiesterase 4D in mice shortens \u03b12-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest. 2002, 110: 1045-1052.","journal-title":"J Clin Invest"},{"key":"331_CR14","doi-asserted-by":"publisher","first-page":"4408","DOI":"10.1021\/ja01363a021","volume":"53","author":"AS Gomm","year":"1931","unstructured":"Gomm AS, Nierenstein M: The exhaustive O-methylation of quercetin. J Am Chem Soc. 1931, 53: 4408-4411. 10.1021\/ja01363a021.","journal-title":"J Am Chem Soc"},{"key":"331_CR15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1021\/bi00800a014","volume":"10","author":"WJ Thompson","year":"1971","unstructured":"Thompson WJ, Appleman MM: Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry. 1971, 10: 311-316. 10.1021\/bi00778a018.","journal-title":"Biochemistry"},{"key":"331_CR16","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1016\/0006-2952(89)90631-X","volume":"38","author":"HS Ahn","year":"1989","unstructured":"Ahn HS, Crim W, Romano M, Sybertz E, Pitts B: Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol. 1989, 38: 3331-3339. 10.1016\/0006-2952(89)90631-X.","journal-title":"Biochem Pharmacol"},{"key":"331_CR17","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0026-895X(25)10279-4","volume":"29","author":"SA Harrison","year":"1986","unstructured":"Harrison SA, Reifsnyder DH, Gallis B, Cadd GG, Beavo JA: Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol Pharmacol. 1986, 29: 506-514.","journal-title":"Mol Pharmacol"},{"key":"331_CR18","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1042\/bj2410535","volume":"241","author":"ML Reeves","year":"1987","unstructured":"Reeves ML, Leigh BK, England PJ: The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochem J. 1987, 241: 535-541.","journal-title":"Biochem J"},{"key":"331_CR19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976, 72: 248-254. 10.1016\/0003-2697(76)90527-3.","journal-title":"Anal Biochem"},{"key":"331_CR20","doi-asserted-by":"crossref","unstructured":"Schneider HH, Schmiechen R, Brezinski M, Seidler J: Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol. 1986, 105-115. 127:","DOI":"10.1016\/0014-2999(86)90210-4"},{"key":"331_CR21","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1124\/jpet.102.047407","volume":"305","author":"Y Zhao","year":"2003","unstructured":"Zhao Y, Zhang HT, O'Donnell JM: Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram. J Pharmacol Exp Ther. 2003, 305: 565-572. 10.1124\/jpet.102.047407.","journal-title":"J Pharmacol Exp Ther"},{"key":"331_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1164\/ajrccm.163.1.2001118","volume":"163","author":"A Kanehiro","year":"2001","unstructured":"Kanehiro A, Ikemura T, Makela MJ, Lahn M, Joetham A, Dakhama A, Gelfand EW: Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. Am J Respir Crit Care Med. 2001, 163: 173-184.","journal-title":"Am J Respir Crit Care Med"},{"key":"331_CR23","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ejphar.2009.03.078","volume":"612","author":"DY Kim","year":"2009","unstructured":"Kim DY, Park JW, Jeoung D, Ro JY: Celastrol suppresses allergen-induced airway inflammation in a mouse allergic asthma model. Eur J Pharmacol. 2009, 612: 98-105. 10.1016\/j.ejphar.2009.03.078.","journal-title":"Eur J Pharmacol"},{"key":"331_CR24","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1164\/ajrccm.156.3.9606031","volume":"156","author":"E Hamelmann","year":"1997","unstructured":"Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, Gelfand EW: Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med. 1997, 156: 766-775.","journal-title":"Am J Respir Crit Care Med"},{"key":"331_CR25","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0022-1759(99)00049-6","volume":"226","author":"GE Winterrowd","year":"1999","unstructured":"Winterrowd GE, Chin JE: Flow cytometric detection of antigen-specific cytokine responses in lung T cells in a murine model of pulmonary inflammation. J Immunol Methods. 1999, 226: 105-118. 10.1016\/S0022-1759(99)00049-6.","journal-title":"J Immunol Methods"},{"key":"331_CR26","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1165\/rcmb.2003-0178OC","volume":"30","author":"BN Melgert","year":"2004","unstructured":"Melgert BN, Postma DS, Geerlings M, Luinge MA, Klok PA, van der Strate BW, Kerstjens HA, Timens W, Hylkema MN: Short-term smoke exposure attenuates ovalbumin-induced airway inflammation in allergic mice. Am J Respir Cell Mol Biol. 2004, 30: 880-885.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"331_CR27","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1056\/NEJM200102013440507","volume":"344","author":"WW Busse","year":"2001","unstructured":"Busse WW, Lemanske RF: Asthma. N Engl J Med. 2001, 344: 350-362. 10.1056\/NEJM200102013440507.","journal-title":"N Engl J Med"},{"key":"331_CR28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2353\/ajpath.2009.071151","volume":"174","author":"P Bogaert","year":"2009","unstructured":"Bogaert P, Tournoy KG, Naessens T, Grooten J: Where asthma and hypersensitivity pneumonitis meet and differ: noneosinophilic severe asthma. Am J Pathol. 2009, 174: 3-13. 10.2353\/ajpath.2009.071151.","journal-title":"Am J Pathol"},{"key":"331_CR29","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.4049\/jimmunol.174.2.1097","volume":"174","author":"H Revets","year":"2005","unstructured":"Revets H, Pynaert G, Grooten J, De Baetselier P: Lipoprotein I, a TLR2\/4 ligand modulates Th2-driven allergic immune responses. J Immunol. 2005, 174: 1097-1103.","journal-title":"J Immunol"},{"key":"331_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/ecam\/nek022","volume":"3","author":"A Vojdani","year":"2006","unstructured":"Vojdani A, Erde J: Regulatory T cells, a potent immunoregulatory target for CAM researchers: the ultimate antagonist (I). Evid Based Complement Alternat Med. 2006, 3: 25-30. 10.1093\/ecam\/nek022.","journal-title":"Evid Based Complement Alternat Med"},{"key":"331_CR31","doi-asserted-by":"publisher","first-page":"6482","DOI":"10.4049\/jimmunol.169.11.6482","volume":"169","author":"C Taube","year":"2002","unstructured":"Taube C, Duez C, Cui ZH, Takeda K, Rha YH, Park JW, Balhorn A, Donaldson DD, Dakhama A, Gelfand EW: The role of IL-13 in established allergic airway disease. J Immunol. 2002, 169: 6482-6489.","journal-title":"J Immunol"},{"key":"331_CR32","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1165\/rcmb.2002-0032OC","volume":"28","author":"BB Vargaftig","year":"2003","unstructured":"Vargaftig BB, Singer M: Leukotrienes mediate murine bronchopulmonary hyperreactivity, inflammation, and part of mucosal metaplasia and tissue injury induced by recombinant murine interleukin-13. Am J Respir Cell Mol Biol. 2003, 28: 410-419. 10.1165\/rcmb.2002-0032OC.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"331_CR33","first-page":"695","volume-title":"Principles of Pharmacology-The Pathophysiologic Basis of Drug Therapy","author":"J Tucker","year":"2005","unstructured":"Tucker J, Fanta CH: Integrative inflammation pharmacology: Asthma. Principles of Pharmacology-The Pathophysiologic Basis of Drug Therapy. Edited by: Golan DE, Tashjian AH Jr, Armstrong EJ, Galanter JM, Armstrong AW, Arnaout RA, Rose HS. 2005, Philadelphia: Lippincott Williams & Wilkins, 695-705."},{"key":"331_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1084\/jem.183.1.195","volume":"183","author":"PS Foster","year":"1996","unstructured":"Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG: Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med. 1996, 183: 195-201. 10.1084\/jem.183.1.195.","journal-title":"J Exp Med"},{"key":"331_CR35","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1084\/jem.20020805","volume":"196","author":"E Clayton","year":"2002","unstructured":"Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, Gray A, Humphries LA, Rawlings D, Reynolds H, Vigorito E, Turner M: A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med. 2002, 196: 753-763. 10.1084\/jem.20020805.","journal-title":"J Exp Med"},{"key":"331_CR36","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","volume":"297","author":"K Okkenhaug","year":"2002","unstructured":"Okkenhaug K, Bilancio A, Farjot G, Priddle H, Sancho S, Peskett E, Pearce W, Meek SE, Salpekar A, Waterfield MD, Smith AJ, Vanhaesebroeck B: Impaired B and T cell antigen receptor signaling in p110\u03b4 PI 3-kinase mutant mice. Science. 2002, 297: 1031-1034.","journal-title":"Science"},{"key":"331_CR37","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1096\/fj.05-5045com","volume":"20","author":"KS Lee","year":"2006","unstructured":"Lee KS, Lee HK, Hayflick JS, Lee YC, Puri KD: Inhibition of phosphoinositide 3-kinase delta attenuates allergic airway inflammation and hyperresponsiveness in murine asthma model. FASEB J. 2006, 20: 455-465. 10.1096\/fj.05-5045com.","journal-title":"FASEB J"},{"key":"331_CR38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1084\/jem.188.2.399","volume":"188","author":"CL Emson","year":"1998","unstructured":"Emson CL, Bell SE, Jones A, Wisden W, McKenzie AN: Interleukin (IL)-4-independent induction of immunoglobulin (Ig)E, and perturbation of T cell development in transgenic mice expressing IL-13. J Exp Med. 1998, 188: 399-404. 10.1084\/jem.188.2.399.","journal-title":"J Exp Med"},{"key":"331_CR39","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S1074-7613(00)80324-6","volume":"6","author":"CM Snapper","year":"1997","unstructured":"Snapper CM, Marcu KB, Zelazowski P: The immunoglobulin class switch: beyond \"accessibility\". Immunity. 1997, 6: 217-223. 10.1016\/S1074-7613(00)80324-6.","journal-title":"Immunity"},{"key":"331_CR40","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-3-642-59641-4_6","volume":"245","author":"J Stavnezer","year":"2000","unstructured":"Stavnezer J: Molecular processes that regulate class switching. Curr Top Microbiol Immunol. 2000, 245: 127-168. 10.1007\/978-3-642-59641-4_6.","journal-title":"Curr Top Microbiol Immunol"},{"key":"331_CR41","first-page":"239","volume-title":"Human Pharmacology Molecular to Clinical","author":"DP Westfall","year":"1998","unstructured":"Westfall DP, Gerthoffer WT, Webb RC: Vasodilators and nitric oxide synthase. Human Pharmacology Molecular to Clinical. Edited by: Brody TM, Larner J, Minneman KP. 1998, St. Louis: Mosby, 239-247."},{"key":"331_CR42","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0140-6736(05)17708-3","volume":"365","author":"BJ Lipworth","year":"2005","unstructured":"Lipworth BJ: Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet. 2005, 365: 167-175. 10.1016\/S0140-6736(05)17708-3.","journal-title":"Lancet"},{"key":"331_CR43","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0022-3565(24)29537-9","volume":"297","author":"A Hatzelmann","year":"2001","unstructured":"Hatzelmann A, Schudt C: Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther. 2001, 297: 267-279.","journal-title":"J Pharmacol Exp Ther"},{"key":"331_CR44","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/S0140-6736(09)61252-6","volume":"374","author":"LM Fabbri","year":"2009","unstructured":"Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF: Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009, 374: 695-703. 10.1016\/S0140-6736(09)61252-6.","journal-title":"Lancet"},{"key":"331_CR45","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","volume":"374","author":"PM Calverley","year":"2009","unstructured":"Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ: Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009, 374: 685-694. 10.1016\/S0140-6736(09)61255-1.","journal-title":"Lancet"},{"key":"331_CR46","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1124\/jpet.103.059097","volume":"308","author":"R Draheim","year":"2004","unstructured":"Draheim R, Egerland U, Rundfeldt C: Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)- [1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations. J Pharmacol Exp Ther. 2004, 308: 555-563.","journal-title":"J Pharmacol Exp Ther"},{"key":"331_CR47","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1124\/jpet.103.053942","volume":"307","author":"H Kuss","year":"2003","unstructured":"Kuss H, Hoefgen N, Johanssen S, Kronbach T, Rundfeldt C: In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)- [1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration. J Pharmacol Exp Ther. 2003, 307: 373-385. 10.1124\/jpet.103.053942.","journal-title":"J Pharmacol Exp Ther"},{"key":"331_CR48","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1211\/jpp.57.12.0011","volume":"57","author":"J Hoppmann","year":"2005","unstructured":"Hoppmann J, Baumer W, Galetzka C, Hofgen N, Kietzmann M, Rundfeldt C: The phosphodiesterase 4 inhibitor AWD 12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005, 57: 1609-1617.","journal-title":"J Pharm Pharmacol"},{"key":"331_CR49","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/bjp.2008.297","volume":"155","author":"MA Giembycz","year":"2008","unstructured":"Giembycz MA: Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?. Br J Pharmacol. 2008, 155: 288-290.","journal-title":"Br J Pharmacol"},{"key":"331_CR50","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1517\/13543770903313753","volume":"19","author":"L Pages","year":"2009","unstructured":"Pages L, Gavalda A, Lehner MD: PDE4 inhibitors: a review of current developments (2005-2009). Expert Opin Ther Pat. 2009, 19: 1501-1519. 10.1517\/13543770903313753.","journal-title":"Expert Opin Ther Pat"},{"key":"331_CR51","first-page":"495","volume":"11","author":"G Higgs","year":"2010","unstructured":"Higgs G: Is PDE4 too difficult a drug target?. Curr Opin Investig Drugs. 2010, 11: 495-498.","journal-title":"Curr Opin Investig Drugs"},{"key":"331_CR52","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1465-9921-11-26","volume":"11","author":"D Singh","year":"2010","unstructured":"Singh D, Petavy F, Macdonald AJ, Lazaar AL, O'Connor BJ: The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Respir Res. 2010, 11: 26-34. 10.1186\/1465-9921-11-26.","journal-title":"Respir Res"},{"key":"331_CR53","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1185\/030079908X301866","volume":"24","author":"AB Gottlieb","year":"2008","unstructured":"Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C: An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast. Curr Med Res Opin. 2008, 24: 1529-1538. 10.1185\/030079908X301866.","journal-title":"Curr Med Res Opin"},{"key":"331_CR54","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nbt.1598","volume":"28","author":"AB Burgin","year":"2010","unstructured":"Burgin AB, Magnusson OT, Singh J, Witte P, Staker BL, Bjornsson JM, Thorsteinsdottir M, Hrafnsdottir S, Hagen T, Kiselyov AS, Stewart LJ, Gurney ME: Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol. 2010, 28: 63-70. 10.1038\/nbt.1598.","journal-title":"Nat Biotechnol"},{"key":"331_CR55","first-page":"323","volume-title":"Cyclic Nucleotide Phosphodiesterases in Health and Disease","author":"SL Jin","year":"2007","unstructured":"Jin SL, Richter W, Conti M: Insights into the physiological functions of PDE4 from knockout mice. Cyclic Nucleotide Phosphodiesterases in Health and Disease. Edited by: Beavo JA, Francis SH, Houslay MD. 2007, Boca Raton: CRC Press, 323-346."},{"key":"331_CR56","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejphar.2005.12.059","volume":"533","author":"CK Fan","year":"2006","unstructured":"Fan CK: Phosphodiesterase inhibitors in airways disease. Eur J Pharmacol. 2006, 533: 110-117. 10.1016\/j.ejphar.2005.12.059.","journal-title":"Eur J Pharmacol"},{"key":"331_CR57","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0028-3908(00)00142-8","volume":"40","author":"A Robichaud","year":"2001","unstructured":"Robichaud A, Savoie C, Stamatiou PB, Tattersall FD, Chan CC: PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology. 2001, 40: 262-269. 10.1016\/S0028-3908(00)00142-8.","journal-title":"Neuropharmacology"}],"container-title":["Journal of Biomedical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1423-0127-18-84.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T16:24:10Z","timestamp":1741969450000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/1423-0127-18-84"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,11]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["331"],"URL":"https:\/\/doi.org\/10.1186\/1423-0127-18-84","relation":{},"ISSN":["1423-0127"],"issn-type":[{"value":"1423-0127","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,11]]},"assertion":[{"value":"29 September 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"84"}}